Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 195 entries
View as:

SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05582122 Org: User:
Start: 04/03/24 End: 04/01/31 Due: 04/01/32

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01805271 Org: User:
Start: 03/31/13 End: 06/30/30 Due: 06/30/31

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03943667 Org: User:
Start: 05/23/19 End: 04/26/22 Due: 04/26/23

Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01247233 Org: User:
Start: 12/27/10 End: 10/31/25 Due: 10/31/26

Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00955240 Org: User:
Start: 03/31/09 End: 11/26/10 Due: 11/26/11

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06680596 Org: User:
Start: 07/30/25 End: 08/01/29 Due: 08/01/30

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00667069 Org: User:
Start: 04/07/08 End: 05/24/22 Due: 05/24/23

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03643133 Org: User:
Start: 10/23/18 End: 10/31/33 Due: 10/31/34

Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

Phase: N/A Priority: Normal
NCT ID: NCT06653777 Org: User:
Start: 03/27/25 End: 06/30/28 Due: 06/30/29

EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies

Phase: N/A Priority: Normal
NCT ID: NCT02701907 Org: User:
Start: 12/31/16 End: 04/17/22 Due: 04/17/23

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Phase: N/A Priority: Normal
NCT ID: NCT05078047 Org: User:
Start: 03/08/22 End: 03/07/27 Due: 03/07/28

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01442935 Org: User:
Start: 02/28/11 End: 01/31/21 Due: 01/31/22

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03799835 Org: User:
Start: 01/17/19 End: 10/31/28 Due: 10/31/29

Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase: N/A Priority: Normal
NCT ID: NCT00006050 Org: User:
Start: 04/04/99 End: 04/04/03 Due: 04/04/04

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06846346 Org: User:
Start: 09/30/25 End: 09/30/28 Due: 09/30/29

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

Phase: N/A Priority: Normal
NCT ID: NCT06276465 Org: User:
Start: 10/07/24 End: 10/07/32 Due: 10/07/33

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01526135 Org: User:
Start: 04/16/12 End: 07/16/21 Due: 07/16/22

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Phase: N/A Priority: Normal
NCT ID: NCT05617963 Org: User:
Start: 03/24/23 End: 02/24/30 Due: 02/24/31

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02818725 Org: User:
Start: 06/30/10 End: 09/30/17 Due: 09/30/18

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Phase: N/A Priority: Normal
NCT ID: NCT03722108 Org: User:
Start: 02/07/19 End: 05/19/22 Due: 05/19/23

Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00227708 Org: User:
Start: 06/30/05 End: 08/29/06 Due: 08/29/07

Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00967031 Org: User:
Start: 04/30/09 End: - Due: -

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003652 Org: User:
Start: 01/04/99 End: 03/31/07 Due: 03/31/08

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Phase: N/A Priority: Normal
NCT ID: NCT06475352 Org: User:
Start: 01/20/25 End: 01/31/30 Due: 01/31/31

Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01363466 Org: User:
Start: 05/31/03 End: 11/30/06 Due: 11/30/07